7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Histiocytosis, Langerhans-Cell D006646 1 associated lipids
Jaw, Edentulous, Partially D007576 1 associated lipids
Bone Diseases, Endocrine D001849 1 associated lipids
Urologic Neoplasms D014571 2 associated lipids
Tooth Mobility D014086 2 associated lipids
Microvascular Angina D017566 2 associated lipids
Otosclerosis D010040 2 associated lipids
Root Resorption D012391 2 associated lipids
Bacteroidaceae Infections D016866 2 associated lipids
Bone Marrow Neoplasms D019046 2 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Wang Y et al. LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells. 2011 Mol. Cell. Endocrinol. pmid:21291955
Szulc P et al. Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. 2011 J. Clin. Endocrinol. Metab. pmid:21565793
Zhang M et al. EP1(-/-) mice have enhanced osteoblast differentiation and accelerated fracture repair. 2011 J. Bone Miner. Res. pmid:20939055
Zhang Y et al. Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone. 2011 PLoS ONE pmid:21897843
Tanaka H et al. Expression of RANKL/OPG during bone remodeling in vivo. 2011 Biochem. Biophys. Res. Commun. pmid:21771583
Meulman T et al. Impact of Porphyromonas gingivalis inoculation on ligature-induced alveolar bone loss. A pilot study in rats. 2011 J. Periodont. Res. pmid:21726226
Yang L et al. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation. 2011 Chin. Med. J. pmid:22088466
Reinhard H et al. Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. 2011 Cardiovasc Diabetol pmid:21801376
Yang XY et al. [Influence of surface modification of titanium on OPG/RANKL mRNA expression in MG-63 human osteoblast-like cells]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:21868322
Malliga DE et al. The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review. 2011 Wien Med Wochenschr pmid:21870142
Guo HL et al. [Experimental study on the mechanism of icariin improving human osteoblasts proliferation and the expression of OPG protein]. 2011 Zhongguo Gu Shang pmid:21870401
McGrath EE OPG/RANKL/RANK pathway as a therapeutic target in cancer. 2011 J Thorac Oncol pmid:21849854
Findlay DM and Atkins GJ Relationship between serum RANKL and RANKL in bone. 2011 Osteoporos Int pmid:21850548
Christoforidis A et al. Comparative study of dual energy X-ray absorptiometry and quantitative ultrasonography with the use of biochemical markers of bone turnover in boys with haemophilia. 2011 Haemophilia pmid:20825502
Embree M et al. Role of subchondral bone during early-stage experimental TMJ osteoarthritis. 2011 J. Dent. Res. pmid:21917603
Hope S et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. 2011 J Psychiatr Res pmid:21889167
Shin M et al. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. 2011 Carcinogenesis pmid:21890459
Grigoropoulou P et al. The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. 2011 Curr. Med. Chem. pmid:21919846
Riancho JA and Delgado-Calle J [Osteoblast-osteoclast interaction mechanisms]. 2011 Reumatol Clin pmid:21924211
Peng S et al. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. 2011 Bone pmid:21925296
Fan R et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin expression in chronic apical periodontitis: possible association with inflammatory cells. 2011 Chin. Med. J. pmid:21933620
Khoshniat S et al. Phosphate-dependent stimulation of MGP and OPN expression in osteoblasts via the ERK1/2 pathway is modulated by calcium. 2011 Bone pmid:21147284
Durual S et al. Titanium nitride oxide coating on rough titanium stimulates the proliferation of human primary osteoblasts. 2011 Clin Oral Implants Res pmid:21087318
Ashley DT et al. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. 2011 Metab. Clin. Exp. pmid:21087777
Tekkesin MS et al. The role of RANK/RANKL/OPG signalling pathways in osteoclastogenesis in odontogenic keratocysts, radicular cysts, and ameloblastomas. 2011 Head Neck Pathol pmid:21643971
Jiang JQ et al. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. 2011 Nephrology (Carlton) pmid:21649792
Choi EM Honokiol isolated from Magnolia officinalis stimulates osteoblast function and inhibits the release of bone-resorbing mediators. 2011 Int. Immunopharmacol. pmid:21621646
Ueland T et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. 2011 J. Intern. Med. pmid:21623962
Wheater G et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. 2011 Osteoporos Int pmid:21625887
Colombini A et al. Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing. 2011 Int Orthop pmid:20623281
Kanayama K et al. Osteoclast and osteoblast activities on carbonate apatite plates in cell cultures. 2011 J Biomater Appl pmid:20624844
Baloul SS et al. Mechanism of action and morphologic changes in the alveolar bone in response to selective alveolar decortication-facilitated tooth movement. 2011 Am J Orthod Dentofacial Orthop pmid:21435543
Wang AY Consequences of chronic inflammation in peritoneal dialysis. 2011 Semin. Nephrol. pmid:21439430
Ikeda K et al. Conditional expression of constitutively active estrogen receptor α in osteoblasts increases bone mineral density in mice. 2011 FEBS Lett. pmid:21439958
Teramachi J et al. Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis. 2011 Lab. Invest. pmid:21339747
Katz J et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. 2011 Int J Oral Maxillofac Surg pmid:21396799
Bitto A et al. Genistein aglycone effect on bone loss is not enhanced by supplemental calcium and vitamin D3: a dose ranging experimental study. 2011 Phytomedicine pmid:21397481
Di Bartolo BA et al. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. 2011 Cardiovasc. Res. pmid:21447702
Ho TY et al. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. 2011 Bone pmid:21419242
Hemingway F et al. In vitro generation of mature human osteoclasts. 2011 Calcif. Tissue Int. pmid:21960377
Dimitriadis K et al. Exercise blood pressure response is related to asymmetric dimethylarginine and osteoprotegerin in hypertension. 2011 Int. J. Cardiol. pmid:21975354
Yao Y et al. Synergistic enhancement of new bone formation by recombinant human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs. 2011 J. Oral Maxillofac. Surg. pmid:22018252
Brown TT et al. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. 2011 Antivir. Ther. (Lond.) pmid:22024522
Hsieh TP et al. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis. 2011 Phytomedicine pmid:20554188
Yener S et al. Is there an association between non-functioning adrenal adenoma and endothelial dysfunction? 2011 J. Endocrinol. Invest. pmid:20530985
de Souza JA et al. Expression of suppressor of cytokine signaling 1 and 3 in ligature-induced periodontitis in rats. 2011 Arch. Oral Biol. pmid:21511249
Claro T et al. Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. 2011 PLoS ONE pmid:21525984
Giro G et al. Influence of estrogen deficiency on bone around osseointegrated dental implants: an experimental study in the rat jaw model. 2011 J. Oral Maxillofac. Surg. pmid:21530046
Won KY et al. RANK signalling in bone lesions with osteoclast-like giant cells. 2011 Pathology pmid:21532526
Naot D et al. Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts. 2011 Bone pmid:21515435
Aydin H et al. Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats. 2011 Minerva Endocrinol. pmid:21519319
Huang CH et al. Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. 2011 Rheumatology (Oxford) pmid:20974615
Pepene CE et al. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. 2011 Eur. J. Endocrinol. pmid:20974706
Sipos W et al. OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers. 2011 Horm. Metab. Res. pmid:22161252
Akinci B et al. Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome. 2011 Diabetes Res. Clin. Pract. pmid:20970873
Toffoli B et al. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. 2011 Mol. Cell. Endocrinol. pmid:20832449
Rauch A et al. An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. 2011 FASEB J. pmid:21233489
Ueland T et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. 2011 Circ Heart Fail pmid:21216833
Tang T et al. Effect of water-soluble P-chitosan and S-chitosan on human primary osteoblasts and giant cell tumor of bone stromal cells. 2011 Biomed Mater pmid:21205994
Attia EA et al. Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. 2011 Int. J. Dermatol. pmid:21182499
Sun Z and Tee BC Molecular variations related to the regional differences in periosteal growth at the mandibular ramus. 2011 Anat Rec (Hoboken) pmid:21157918
Basu R et al. Effects of physiological variations in circulating insulin levels on bone turnover in humans. 2011 J. Clin. Endocrinol. Metab. pmid:21325461
Kamiya N et al. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis. 2011 Int. J. Clin. Oncol. pmid:21327451
Eslami B et al. Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. 2011 Calcif. Tissue Int. pmid:21327765
Jørgensen L et al. Serum osteoprotegerin levels are related to height loss: the Tromsø Study. 2011 Eur. J. Epidemiol. pmid:21331661
Yuan H et al. Receptor activator of nuclear factor kappa B ligand antagonists inhibit tissue inflammation and bone loss in experimental periodontitis. 2011 J. Clin. Periodontol. pmid:22092474
Feng Z et al. An oligodeoxynucleotide with promising modulation activity for the proliferation and activation of osteoblast. 2011 Int J Mol Sci pmid:21731457
Mai QG et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. 2011 J. Cell. Biochem. pmid:21618594
Garcia VG et al. Treatment of experimental periodontal disease with antimicrobial photodynamic therapy in nicotine-modified rats. 2011 J. Clin. Periodontol. pmid:22092666
Kornak U Animal models with pathological mineralization phenotypes. 2011 Joint Bone Spine pmid:21550285
Santini D et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. 2011 PLoS ONE pmid:21559440
Mariúba MV et al. Effect of triiodothyronine on the maxilla and masseter muscles of the rat stomatognathic system. 2011 Braz. J. Med. Biol. Res. pmid:21584440
Kuczkowski J et al. Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media. 2010 Nov-Dec Am J Otolaryngol pmid:20015790
Kuczkowski J et al. [Molecular control of bone resorption in chronic otitis media with cholesteatoma]. 2010 Jul-Aug Otolaryngol Pol pmid:20873097
Reyes-García R et al. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis. 2010 Jan-Feb Menopause pmid:19574937
Mori K et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. 2010 Feb-Mar Angiology pmid:19147525
Jurado S et al. Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures. 2010 Osteoporos Int pmid:19436932
Moran CS et al. Association of PPARgamma allelic variation, osteoprotegerin and abdominal aortic aneurysm. 2010 Clin. Endocrinol. (Oxf) pmid:19438902
Yilmaz Y et al. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. 2010 Scand. J. Clin. Lab. Invest. pmid:20942739
Kobayashi-Sakamoto M et al. Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells. 2010 Eur. J. Haematol. pmid:20331738
Vik A et al. Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromsø Study. 2010 J. Thromb. Haemost. pmid:20738762
Ochi H et al. The roles of TNFR1 in lipopolysaccharide-induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival. 2010 J. Orthop. Res. pmid:19890995
Rianthavorn P et al. Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium. 2010 Pediatr. Nephrol. pmid:20676692
Jules J et al. Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. 2010 Expert Opin. Ther. Targets pmid:20678025
Fong JE et al. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase. 2010 J. Biol. Chem. pmid:20679341
Cawley NX et al. Obese carboxypeptidase E knockout mice exhibit multiple defects in peptide hormone processing contributing to low bone mineral density. 2010 Am. J. Physiol. Endocrinol. Metab. pmid:20460579
Jiang R et al. High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. 2010 Int. J. Cancer pmid:19728335
Rhee EJ et al. The relationship between Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL) gene polymorphism and aortic calcification in Korean women. 2010 Endocr. J. pmid:20431232
McAllister SS and Weinberg RA Tumor-host interactions: a far-reaching relationship. 2010 J. Clin. Oncol. pmid:20644094
Gupta N et al. IL-3 inhibits human osteoclastogenesis and bone resorption through downregulation of c-Fms and diverts the cells to dendritic cell lineage. 2010 J. Immunol. pmid:20644169
van Tuyl LH et al. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. 2010 Ann. Rheum. Dis. pmid:20525836
Zhang L et al. Cell-based osteoprotegerin therapy for debris-induced aseptic prosthetic loosening on a murine model. 2010 Gene Ther. pmid:20428210
Kim YG et al. Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes. 2010 Arthritis Rheum. pmid:20112365
Lee JE et al. Impact of ENPP1 and MMP3 gene polymorphisms on aortic calcification in patients with type 2 diabetes in a Korean population. 2010 Diabetes Res. Clin. Pract. pmid:20092902
Flyvbjerg A Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. 2010 Nat Rev Endocrinol pmid:20098449
Scudla V et al. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. 2010 Neoplasma pmid:20099972
Elias LS et al. Markers of bone remodeling in neoplastic and bone-related lesions. 2010 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:20955951
Nozaki K et al. Effect of cyclic mechanical loading on osteoclast recruitment in periodontal tissue. 2010 J. Periodont. Res. pmid:19602121
O'Sullivan EP et al. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. 2010 Thromb. Res. pmid:20932553
Eagan TM et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. 2010 Eur. Respir. J. pmid:19643942

Table of Content